Buys in Diabetes and Wound Care

posted in: Writing | 0

David Evanson and William Plovanic, Spring, 2012

Going into the Q1/12 earnings season for diabetes and wound care companies, Canaccord Genuity medical devices analyst William Plovanic noted his long term buys in the field were DexCom (DXCM : NASDAQ : $9.97 | BUY), Insulet (PODD : NASDAQ : $18.35 | BUY), Derma Sciences (DSCI : NASDAQ : $9.67 | BUY).

He said, “We believe improvements in the broader economy, with consumer confidence and unemployment levels improving, may offset typical seasonality and therefore DexCom and Insulet may experience strong Q1/12 results.”

He added, “Alternatively, the broader wound care market is relatively insulated to economic pressures due to the non-discretionary nature of chronic wounds, and Derma Sciences is well positioned due to its differentiated advanced wound care portfolio and new product cycle.”